Roche Holding AG (OTCMKTS:RHHBY) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Roche has a “Moderate Buy” consensus rating among 12 analysts, split evenly between six buy and six hold recommendations. The average 12-month price target is $60, implying potential upside from the $54.63 opening price.
• Analyst sentiment has recently improved, with Morgan Stanley upgrading Roche to “overweight” and RBC initiating coverage with an “outperform” rating, while HSBC maintained a “hold” recommendation.
• Roche reported positive Phase III results for its Lunsumio-based lymphoma regimen, supporting potential growth in blood-cancer treatments; however, competition from TG Therapeutics remains a risk to market share and pricing power.

Roche Holding AG (OTCMKTS:RHHBY - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the twelve analysts that are currently covering the stock, Marketbeat reports. Six analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $60.00.

Several equities analysts have recently commented on RHHBY shares. Morgan Stanley upgraded shares of Roche from an "equal weight" rating to an "overweight" rating and set a $63.00 price objective on the stock in a report on Friday, August 7th. Royal Bank Of Canada started coverage on Roche in a report on Tuesday, September 8th. They set an "outperform" rating for the company. Zacks Research upgraded shares of Roche from a "strong sell" rating to a "hold" rating in a report on Monday, August 24th. Finally, HSBC reaffirmed a "hold" rating on shares of Roche in a research note on Thursday, September 10th.

Roche Price Performance

OTCMKTS:RHHBY opened at $54.63 on Friday. The stock has a 50 day moving average of $54.67 and a two-hundred day moving average of $52.44. Roche has a 12 month low of $39.50 and a 12 month high of $60.85. The company has a current ratio of 1.38, a quick ratio of 1.12 and a debt-to-equity ratio of 0.72.

More Roche News

Here are the key news stories impacting Roche this week:

• Positive Sentiment: Roche and Genentech said the Lunsumio-based regimen met the primary endpoint in the Phase III CELESTIMO study for patients with previously treated follicular lymphoma. Lunsumio combined with Revlimid significantly improved progression-free survival compared with rituximab plus Revlimid, while reports also cited improved overall survival. The results strengthen the drug’s potential expansion in a major blood-cancer market and could support future revenue growth. Roche’s Lunsumio-based regimen significantly improves progression-free survival
• Positive Sentiment: Roche is partnering with Dualitas Therapeutics on bispecific-antibody research. The collaboration expands Roche’s drug-discovery capabilities and may create additional pipeline opportunities, although financial terms and the timing of potential products were not disclosed. Dualitas Therapeutics and Roche partner on bispecific antibody research
• Neutral Sentiment: Roche and Genentech opened an Innovation Center in Boston focused on cardiovascular, renal and metabolic diseases. The facility enhances the company’s research presence and collaboration network, but its financial benefits are longer term and are unlikely to materially affect near-term earnings. Roche announces the opening of its Boston Innovation Center
• Negative Sentiment: Coverage highlighting TG Therapeutics’ bullish momentum amid its ongoing rivalry with Roche underscores competitive risk in the hematology market. While the article does not report a new Roche setback, stronger rival positioning could limit market share or pricing power for Roche’s blood-cancer portfolio. TG Therapeutics makes a bullish move amid Roche rivalry

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in RHHBY. Confluence Investment Management LLC boosted its stake in shares of Roche by 1.2% during the 2nd quarter. Confluence Investment Management LLC now owns 20,925 shares of the company's stock valued at $1,074,000 after buying an additional 258 shares during the last quarter. Enterprise Financial Services Corp grew its holdings in Roche by 6.6% during the 1st quarter. Enterprise Financial Services Corp now owns 5,576 shares of the company's stock worth $277,000 after acquiring an additional 345 shares in the last quarter. Archer Investment Corp increased its position in shares of Roche by 7.7% in the 1st quarter. Archer Investment Corp now owns 5,598 shares of the company's stock worth $278,000 after purchasing an additional 398 shares during the last quarter. Diversified Trust Co increased its position in shares of Roche by 0.8% in the 1st quarter. Diversified Trust Co now owns 59,375 shares of the company's stock worth $2,907,000 after purchasing an additional 448 shares during the last quarter. Finally, Fulton Bank N.A. raised its stake in Roche by 5.1% during the second quarter. Fulton Bank N.A. now owns 11,572 shares of the company's stock valued at $597,000 after buying an additional 559 shares in the last quarter.

Roche Company Profile

Roche Holding AG is a Switzerland-based healthcare company that develops and provides pharmaceutical products and diagnostic solutions. Founded in 1896 and headquartered in Basel, Roche operates through two complementary divisions: Pharmaceuticals and Diagnostics.

The Pharmaceuticals division focuses on medicines for oncology, immunology, neuroscience, ophthalmology, hematology and other therapeutic areas. Its portfolio includes treatments such as Ocrevus, Hemlibra, Perjeta, Tecentriq and Vabysmo.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.